Pfizer Inc. (NYSE:PFE) Shares Sold by Sompo Asset Management Co. Ltd.

Sompo Asset Management Co. Ltd. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,510 shares of the biopharmaceutical company’s stock after selling 960 shares during the quarter. Sompo Asset Management Co. Ltd.’s holdings in Pfizer were worth $622,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Wescott Financial Advisory Group LLC increased its position in shares of Pfizer by 94.1% during the 3rd quarter. Wescott Financial Advisory Group LLC now owns 15,517 shares of the biopharmaceutical company’s stock valued at $449,000 after purchasing an additional 7,522 shares during the period. KKM Financial LLC boosted its stake in Pfizer by 5.4% during the third quarter. KKM Financial LLC now owns 73,671 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 3,767 shares in the last quarter. Palisade Asset Management LLC grew its holdings in Pfizer by 2.6% during the third quarter. Palisade Asset Management LLC now owns 50,235 shares of the biopharmaceutical company’s stock worth $1,454,000 after acquiring an additional 1,295 shares during the period. Canopy Partners LLC raised its position in Pfizer by 4.9% in the third quarter. Canopy Partners LLC now owns 34,588 shares of the biopharmaceutical company’s stock worth $1,001,000 after acquiring an additional 1,618 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in Pfizer by 26.2% in the 3rd quarter. Cerity Partners LLC now owns 1,984,016 shares of the biopharmaceutical company’s stock valued at $57,417,000 after acquiring an additional 412,364 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on PFE. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Stock Performance

Shares of PFE opened at $25.65 on Monday. The company has a market capitalization of $145.36 billion, a PE ratio of 34.66, a PEG ratio of 0.82 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company’s 50 day moving average price is $28.21 and its 200 day moving average price is $28.57. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the previous year, the company posted ($0.17) EPS. Pfizer’s revenue was up 31.2% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.55%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.